Renaissance Technologies LLC decreased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 4.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,001,874 shares of the specialty pharmaceutical company's stock after selling 48,100 shares during the period. Renaissance Technologies LLC owned about 1.66% of Jazz Pharmaceuticals worth $123,381,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Cerity Partners LLC raised its holdings in shares of Jazz Pharmaceuticals by 1.4% in the fourth quarter. Cerity Partners LLC now owns 33,205 shares of the specialty pharmaceutical company's stock worth $3,910,000 after acquiring an additional 448 shares during the last quarter. Quadrant Capital Group LLC increased its holdings in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after buying an additional 101 shares during the last quarter. Envestnet Asset Management Inc. raised its position in shares of Jazz Pharmaceuticals by 36.9% in the 4th quarter. Envestnet Asset Management Inc. now owns 90,742 shares of the specialty pharmaceutical company's stock worth $11,175,000 after buying an additional 24,443 shares during the period. Grantham Mayo Van Otterloo & Co. LLC boosted its holdings in Jazz Pharmaceuticals by 735.2% in the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 25,115 shares of the specialty pharmaceutical company's stock valued at $3,093,000 after acquiring an additional 22,108 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB increased its stake in Jazz Pharmaceuticals by 56.5% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 145,500 shares of the specialty pharmaceutical company's stock worth $17,918,000 after acquiring an additional 52,500 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.
Analyst Ratings Changes
JAZZ has been the topic of several research analyst reports. Royal Bank of Canada reduced their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. Needham & Company LLC reiterated a "buy" rating and set a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday. Barclays reissued an "overweight" rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Wells Fargo & Company upgraded shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their target price for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Finally, UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their price target for the company from $145.00 to $179.00 in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average target price of $187.71.
Read Our Latest Research Report on JAZZ
Jazz Pharmaceuticals Stock Up 1.0 %
Shares of NASDAQ:JAZZ traded up $1.00 during midday trading on Monday, reaching $101.50. The company had a trading volume of 230,209 shares, compared to its average volume of 780,607. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market capitalization of $6.16 billion, a P/E ratio of 14.30, a PEG ratio of 1.04 and a beta of 0.42. The stock's fifty day moving average price is $129.67 and its 200-day moving average price is $122.77.
Insider Transactions at Jazz Pharmaceuticals
In related news, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $123.75, for a total value of $185,625.00. Following the completion of the transaction, the chief executive officer now directly owns 440,307 shares in the company, valued at approximately $54,487,991.25. This trade represents a 0.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Patricia Carr sold 1,140 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the sale, the chief accounting officer now owns 7,012 shares in the company, valued at $966,323.72. The trade was a 13.98 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,736 shares of company stock valued at $4,023,305. Insiders own 4.20% of the company's stock.
About Jazz Pharmaceuticals
(
Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Further Reading
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
